Abstract
The nuclear receptors known as PPARs and LXRs are lipid-activated transcription factors that have emerged as key regulators of lipid metabolism and inflammation. PPARs and LXRs are activated by non-esterified fatty acids and cholesterol metabolites, respectively, and both exert positive and negative control over the expression of a range of metabolic and inflammatory genes. The ability of these nuclear receptors to integrate metabolic and inflammatory signalling makes them attractive targets for intervention in human metabolic diseases, such as atherosclerosis and type 2 diabetes, as well as for the modulation of inflammation and immune responses.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Evans, R. M. The steroid and thyroid hormone receptor superfamily. Science 240, 889–895 (1988).
Mangelsdorf, D. J. & Evans, R. M. The RXR heterodimers and orphan receptors. Cell 83, 841–850 (1995).
Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835–839 (1995).
Giguere, V. Orphan nuclear receptors: from gene to function. Endocr. Rev. 20, 689–725 (1999).
Castrillo, A. & Tontonoz, P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 20, 455–480 (2004).
Glass, C. K. & Ogawa, S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nature Rev. Immunol. 6, 44–55 (2006).
Glass, C. K. & Rosenfeld, M. G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121–141 (2000).
Berger, J. & Moller, D. E. The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409–435 (2002).
Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645–650 (1990).
Kliewer, S. A. et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl Acad. Sci. USA 91, 7355–7359 (1994).
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I. & Spiegelman, B. M. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224–1234 (1994).
Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A. & Evans, R. M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358, 771–774 (1992).
Rosen, E. D. & Spiegelman, B. M. Molecular regulation of adipogenesis. Annu. Rev. Cell Dev. Biol. 16, 145–171 (2000).
Willson, T. M., Lambert, M. H. & Kliewer, S. A. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu. Rev. Biochem. 70, 341–367 (2001).
Tontonoz, P., Hu, E. & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147–1156 (1994).
Barak, Y. et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585–595 (1999).
Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270, 12953–12956 (1995).
Guan, H. P., Ishizuka, T., Chui, P. C., Lehrke, M. & Lazar, M. A. Corepressors selectively control the transcriptional activity of PPARγ in adipocytes. Genes Dev. 19, 453–461 (2005).
Delerive, P. et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J. Biol. Chem. 274, 32048–32054 (1999).
Chung, S. W. et al. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB. J. Biol. Chem. 275, 32681–32687 (2000).
Zingarelli, B. et al. Peroxisome proliferator activator receptor-γ ligands, 15-deoxy-Δ12, 14-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J. Immunol. 171, 6827–6837 (2003).
Kelly, D. et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA. Nature Immunol. 5, 104–112 (2004).
Syrovets, T., Schule, A., Jendrach, M., Buchele, B. & Simmet, T. Ciglitazone inhibits plasmin-induced proinflammatory monocyte activation via modulation of p38 MAP kinase activity. Thromb. Haemost. 88, 274–281 (2002).
Li, M., Pascual, G. & Glass, C. K. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell Biol. 20, 4699–4707 (2000).
Lee, C.-H. et al. Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 302, 453–457 (2003).This paper describes how unliganded PPAR-δ is inflammatory: PPAR-δ sequesters the transcriptional repressor BCL-6 away from the promoters of inflammatory genes. Ligand binding to PPAR-δ releases BCL-6, resulting in the repression of inflammatory gene expression.
Pascual, G. et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437, 759–763 (2005).This paper shows that ligand-driven PPAR- γ transrepression of inflammatory genes occurs by a SUMOylation- and NCOR-dependent pathway.
Straus, D. S. & Glass, C. K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 28, 551–558 (2007).
Adachi, M. et al. Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55, 1104–1113 (2006).
Shah, Y. M., Morimura, K. & Gonzalez, F. J. Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimentally induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G657–G666 (2007).
Wan, Y. et al. Maternal PPARγ protects nursing neonates by suppressing the production of inflammatory milk. Genes Dev. 21, 1895–1908 (2007).This paper shows that endothelial-specific deletion of the gene encoding PPAR-γ modulates the presence of inflammatory lipids in milk produced by mammary glands.
Odegaard, J. I. et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 447, 1116–1120 (2007).This paper reports that the IL-4–STAT6–PPAR-γ signalling axis in monocytes is crucial for their differentiation into alternatively activated macrophages and for innate immunity. It also shows that PPAR-γ signalling in macrophages modulates diet-induced obesity and peripheral insulin resistance.
Huang, J. T. et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400, 378–382 (1999).This paper shows that IL-4-mediated signalling upregulates PPAR-γ expression, and it provides the initial evidence that the IL-4–PPAR-γ signalling pathway regulates macrophage function.
Shoelson, S. E., Lee, J. & Goldfine, A. B. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793–1801 (2006).
Zelcer, N. & Tontonoz, P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116, 607–614 (2006).
Gordon, S. Alternative activation of macrophages. Nature Rev. Immunol. 3, 23–35 (2003).
Vats, D. et al. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab. 4, 13–24 (2006).
Bouhlel, M. A. et al. PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6, 137–143 (2007).
Faveeuw, C. et al. Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett. 486, 261–266 (2000).
Gosset, P. et al. Peroxisome proliferator-activated receptorγ activators affect the maturation of human monocyte-derived dendritic cells. Eur. J. Immunol. 31, 2857–2865 (2001).
Szatmari, I. et al. Activation of PPARγ specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity 21, 95–106 (2004).
Klotz, L. et al. Peroxisome proliferator-activated receptor γ control of dendritic cell function contributes to development of CD4+ T cell anergy. J. Immunol. 178, 2122–2131 (2007).
Szatmari, I. et al. PPARγ regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 110, 3271–3280 (2007).
Dreyer, C. et al. Positive regulation of the peroxisomal β-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol. Cell 77, 67–76 (1993).
Kersten, S. et al. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489–1498 (1999).
Leone, T. C., Weinheimer, C. J. & Kelly, D. P. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96, 7473–7478 (1999).
Staels, B., van Tol, A., Andreu, T. & Auwerx, J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler. Thromb. 12, 286–294 (1992).
Schoonjans, K. et al. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J. 15, 5336–5348 (1996).
Chinetti, G. et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273, 25573–25580 (1998).
Forman, B. M., Chen, J. & Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl Acad. Sci. USA 94, 4312–4317 (1997).
Tordjman, K. et al. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107, 1025–1034 (2001).
Babaev, V. R. et al. Macrophage expression of peroxisome proliferator-activated receptor-α reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 116, 1404–1412 (2007).
Dreyer, C. et al. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879–887 (1992).
Peters, J. M. et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β (δ). Mol. Cell Biol. 20, 5119–5128 (2000).
Michalik, L. et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J. Cell Biol. 154, 799–814 (2001).
Tan, N. S. et al. Critical roles of PPAR β/δ in keratinocyte response to inflammation. Genes Dev. 15, 3263–3277 (2001).
Barak, Y. et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc. Natl Acad. Sci. USA 99, 303–308 (2002).
Chawla, A. et al. PPARδ is a very low-density lipoprotein sensor in macrophages. Proc. Natl Acad. Sci. USA 100, 1268–1273 (2003).
Oliver, W. R. Jr et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl Acad. Sci. USA 98, 5306–5311 (2001).
Gallardo-Soler, A. et al. Arginase I induction by modified lipoproteins in macrophages: a PPAR-γ/δ-mediated effect that links lipid metabolism and immunity. Mol. Endocrinol. 22, 1394–1402 (2008).
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R. & Mangelsdorf, D. J. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 383, 728–731 (1996).
Lehmann, J. M. et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272, 3137–3140 (1997).
Fu, X. et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276, 38378–38387 (2001).
Repa, J. J. & Mangelsdorf, D. J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16, 459–481 (2000).
Tontonoz, P. & Mangelsdorf, D. J. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17, 985–993 (2003).
Peet, D. J. et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 93, 693–704 (1998).
Repa, J. J. et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524–1529 (2000).
Repa, J. J. et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors α and β. J. Biol. Chem. 277, 18793–18800 (2002).
Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 99, 7604–7609 (2002).
Terasaka, N. et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536, 6–11 (2003).
Alberti, S. et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J. Clin. Invest. 107, 565–573 (2001).
Bradley, M. N. et al. Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE. J. Clin. Invest. 117, 2337–2346 (2007).
Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J. & Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med. 9, 213–219 (2003).
Ogawa, S. et al. Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell 122, 707–721 (2005).
Tangirala, R. K. et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl Acad. Sci. USA 99, 11896–11901 (2002).
Ghisletti, S. et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ. Mol. Cell 25, 57–70 (2007).
Selkoe, D. J. The molecular pathology of Alzheimer's disease. Neuron 6, 487–498 (1991).
Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002).
Koldamova, R. P. et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid β secretion. J. Biol. Chem. 278, 13244–13256 (2003).
Sun, Y., Yao, J., Kim, T. W. & Tall, A. R. Expression of liver X receptor target genes decreases cellular amyloid β peptide secretion. J. Biol. Chem. 278, 27688–27694 (2003).
Zhang-Gandhi, C. X. & Drew, P. D. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J. Neuroimmunol. 183, 50–59 (2007).
Koldamova, R. P. et al. The liver X receptor ligand T0901317 decreases amyloid β production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 280, 4079–4088 (2005).
Zelcer, N. et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptors. Proc. Natl Acad. Sci. USA 104, 10601–10606 (2007).This paper shows that deletion of the genes encoding LXRs exacerbates Alzheimer's disease pathology. Conversely, activation of LXRs in microglial cells attenuates amyloid-β-peptide-driven inflammation and preserves phagocytic function.
Hindinger, C. et al. Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 84, 1225–1234 (2006).
Joseph, S. B. et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119, 299–309 (2004).This paper was the first to report that mice lacking LXRs are more susceptible to challenge with L. monocytogenes.
Valledor, A. F. et al. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc. Natl Acad. Sci. USA 101, 17813–17818 (2004).
Birrell, M. A. et al. Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses. J. Biol. Chem. 282, 31882–31890 (2007).
Smoak, K. et al. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J. Immunol. 180, 3305–3312 (2008).
Geyeregger, R. et al. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin. Blood 109, 4288–4295 (2007).
Acknowledgements
P.T. is an investigator of the Howard Hughes Medical Institute. Work in the authors' laboratories was supported by National Institutes of Health grants HL66088 and HL30568 (P.T.) and RR021975 (S.J.B.).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
Reprints and permissions information is available at http://www.nature.com/reprints.
Correspondence should be addressed to P.T. (ptontonoz@mednet.ucla.edu).
Rights and permissions
About this article
Cite this article
Bensinger, S., Tontonoz, P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454, 470–477 (2008). https://doi.org/10.1038/nature07202
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature07202
This article is cited by
-
Activation of LXRs alleviates neuropathic pain-induced cognitive dysfunction by modulation of microglia polarization and synaptic plasticity via PI3K/AKT pathway
Inflammation Research (2024)
-
Duhuo Jisheng decoction alleviates neuroinflammation and neuropathic pain by suppressing microglial M1 polarization: a network pharmacology research
Journal of Orthopaedic Surgery and Research (2023)
-
Lysine metabolism is a novel metabolic tumor suppressor pathway in breast cancer
Oncogene (2023)
-
Capparis spinosa improves non-alcoholic steatohepatitis through down-regulating SREBP-1c and a PPARα-independent pathway in high-fat diet-fed rats
BMC Research Notes (2022)
-
Short-term mercury exposure disrupts muscular and hepatic lipid metabolism in a migrant songbird
Scientific Reports (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.